We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $767M
1-Year Est. Return 119.71%
This Fund
S&P 500
This Quarter Est. Return
+17.33%
1 Year Est. Return
+119.71%
3 Year Est. Return
+244.81%
5 Year Est. Return
+382.5%
10 Year Est. Return
+2,655.81%
AUM
$961M
AUM Growth
+$374M
Cap. Flow
+$41.2M
Cap. Flow %
4.29%
Top 10 Hldgs %
44.93%
Holding
194
New
69
Increased
29
Reduced
39
Closed
48

Top Buys

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$24.6M
2
AGN
Allergan plc
AGN
+$24.2M
3
MRK icon
Merck
MRK
+$22.3M
4
AMGN icon
Amgen
AMGN
+$17.6M
5
ENDP
Endo International plc
ENDP
+$17.6M

Top Sells

Rank Stock Value
1
NVS icon
Novartis
NVS
+$33.6M
2
SHPG
Shire pic
SHPG
+$20.7M
3
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
+$18.2M
4
BIIB icon
Biogen
BIIB
+$11.8M
5
ISRL
Isramco Inc
ISRL
+$11.1M

Sector Composition

Rank Sector Weight
1 Healthcare 59.2%
2 Miscellaneous 33.43%
3 Technology 2.61%
4 Industrials 1.8%
5 Consumer Discretionary 1.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ENTA icon
151
Enanta Pharmaceuticals
ENTA
$365M
– –
-40,000
Closed -$2.03M
ESLT icon
152
Elbit Systems
ESLT
$35.1B
– –
-144,759
Closed -$8.85M
GILD icon
153
CALL
Gilead Sciences
GILD
$187B
– –
-394,200
Closed -$3.95M
GSK icon
154
CALL
GSK
GSK
$102B
– –
-233,040
Closed -$7K
GSK icon
155
GSK
GSK
$102B
– –
-78,560
Closed -$4.2M
ICL icon
156
ICL Group
ICL
$7.14B
– –
-40,116
Closed -$291K
IMUX icon
157
Immunic
IMUX
$141M
– –
-205
Closed -$2.04M
ITRN icon
158
Ituran Location and Control
ITRN
$1.04B
– –
-168,203
Closed -$3.71M
LLY icon
159
Eli Lilly
LLY
$1.03T
– –
-87,100
Closed -$6.01M
LRMR icon
160
Larimar Therapeutics
LRMR
$395M
– –
-6,008
Closed -$2.22M
NICE icon
161
Nice
NICE
$6.17B
– –
-39,652
Closed -$2.01M
NVAX icon
162
Novavax
NVAX
$1.65B
– –
-77
Closed -$9K
PRQR icon
163
ProQR Therapeutics
PRQR
$267M
– –
-130,000
Closed -$2.82M
SRPT icon
164
Sarepta Therapeutics
SRPT
$2.18B
– –
-175,000
Closed -$2.53M
TLPH icon
165
Talphera
TLPH
$60.7M
– –
-5,000
Closed -$673K
VRTX icon
166
Vertex Pharmaceuticals
VRTX
$131B
– –
-30,000
Closed -$3.56M
WIX icon
167
WIX.com
WIX
$3.34B
– –
-59,108
Closed -$1.24M
XLB icon
168
PUT
State Street Materials Select Sector SPDR ETF
XLB
$8.39B
– –
-100,000
Closed -$116K
XLF icon
169
State Street Financial Select Sector SPDR ETF
XLF
$53.4B
– –
-239,221
Closed -$5.19M
EIGR
170
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
– –
-335
Closed -$2.94M
ACOR
171
DELISTED
Acorda Therapeutics
ACOR
– –
-659
Closed -$3.23M
DRNA
172
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
– –
-176,802
Closed -$2.91M
MNK
173
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
– –
-90,940
Closed -$9.01M
BCOM
174
DELISTED
B Communications Ltd
BCOM
– –
-134,174
Closed -$2.42M
MLNX
175
DELISTED
Mellanox Technologies, Ltd.
MLNX
– –
-12,517
Closed -$535K
4 5 6
7
8

Similar funds

ISWM
Independent Solutions Wealth Management Williamsville, New York $766M AUM 31.53% 1-Year Est. Return
ACP
Albar Capital Partners London, United Kingdom $767M AUM 61.96% 1-Year Est. Return
NIM
Nexus Investment Management Toronto, Ontario, Canada $767M AUM 30.97% 1-Year Est. Return
ACM
Arvin Capital Management Austin, Texas $766M AUM 36.51% 1-Year Est. Return
CBT
Crews Bank & Trust Wauchula, Florida $766M AUM 19.5% 1-Year Est. Return
SPIA
Strategic Point Investment Advisors Providence, Rhode Island $767M AUM 17.58% 1-Year Est. Return
CNB
Camden National Bank Camden, Maine $767M AUM 14.32% 1-Year Est. Return
HI
Hendershot Investments Centreville, Virginia $766M AUM 10.81% 1-Year Est. Return

Sphera Funds Management's Q1 2015 Portfolio in Review

As of Q1 2015, Sphera Funds Management held 194 positions worth $961M, up 64% from $587M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Sphera Funds Management deployed $41.2M of net new capital in Q1 2015, opening 69 new positions and adding to 29 existing holdings. Its largest new stake was AbbVie: 407,000 shares worth $23.8M.

By sector, the portfolio is most concentrated in Healthcare at 59% of assets, down from 69% a quarter earlier, followed by Miscellaneous and Technology.

On the sell side, the largest reduction was Novartis, an estimated $33.6M trimmed.

  • Sphera Funds Management's largest Q1 2015 buy was AbbVie: 407,000 shares worth $23.8M.
  • Sphera Funds Management added most to Allergan plc in Q1 2015, an estimated $24.2M increase.
  • Sphera Funds Management's biggest Q1 2015 reduction was Novartis, cutting an estimated $33.6M.
  • Sphera Funds Management fully exited SALIX PHARMACEUTICALS LTD DEL in Q1 2015, selling an estimated $18.2M.
  • Sphera Funds Management's ten largest holdings make up 45% of its $961M portfolio in Q1 2015.
  • Sphera Funds Management opened 69 new positions and closed 48 in Q1 2015.
  • Sphera Funds Management's portfolio value rose 64% quarter-over-quarter to $961M.

Based on Sphera Funds Management's 13F filing for Q1 2015, filed 11 May 2015.